Literature DB >> 10024076

Impact of insulin and body mass index on metabolic and endocrine variables in polycystic ovary syndrome.

M Ciampelli1, A M Fulghesu, F Cucinelli, V Pavone, E Ronsisvalle, M Guido, A Caruso, A Lanzone.   

Abstract

To assess the differential impact of the insulin secretory pattern and obesity on the endocrinometabolic features of the polycystic ovary syndrome (PCOS), we studied 110 PCOS women. Patients underwent a gonadotropin-releasing hormone (GnRH) test, an oral glucose tolerance test (OGTT), and basal evaluation of hormonal and biochemical parameters. Basal androgens and lipids, basal and stimulated gonadotropins, insulin, and glucose levels were measured. Patients were classified into four groups according to the body mass index (BMI) and insulin secretion: normoinsulinemic-lean ([NL] n = 24), normoinsulinemic obese ([NO] n = 24), hyperinsulinemic lean ([HL] n = 17), hyperinsulinemic obese ([HO] n = 45). HL patients showed a higher luteinizing hormone (LH) area under curve (AUC) after GnRH stimulus compared with NL patients (HL v NL, 4,285 +/- 348 v 3,377 +/- 314 IU/L x 120 min, P < .05), whereas we failed to find a statistically significant difference in a similar comparison among obese subjects (HO v NO, 3,606 +/- 302 v 3,129 +/- 602 IU/L x 120 min). A trend toward increased plasma testosterone and decreased sex hormone-binding globulin (SHBG) was found in relation to hyperinsulinemia and obesity, thus resulting in a higher free androgen index (FAI) in groups HL and NO versus NL (HL, 5.54 +/- 0.51; NO, 5.64 +/- 0.49; NL, 4.13 +/- 0.33; P < .05 and P < .01, respectively). The presence of both exaggerated insulin secretion and obesity resulted in a synergistic additive effect on the FAI in the HO group (6.81 +/- 0.34). Concerning the lipoprotein lipid profile, the NL group showed lower plasma triglyceride levels compared with the other three groups, whereas no significant differences were found for nonesterified fatty acid (NEFA) concentrations. Higher low-density lipoprotein cholesterol (LDL-C) and very-low-density lipoprotein cholesterol (VLDL-C) and lower high-density lipoprotein cholesterol (HDL-C) levels were found in the obese groups compared with the lean counterparts, whereas the same parameters did not significantly differ in a comparison between normoinsulinemic and hyperinsulinemic groups. In conclusion, our data suggest an important role of hyperinsulinemia in the LH response to a GnRH stimulus and an independent and synergistic additive effect of obesity and hyperinsulinemia on the FAI in PCOS.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10024076     DOI: 10.1016/s0026-0495(99)90028-8

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  25 in total

1.  Glucose-stimulated oxidative stress in mononuclear cells is related to pancreatic β-cell dysfunction in polycystic ovary syndrome.

Authors:  Steven K Malin; John P Kirwan; Chang Ling Sia; Frank González
Journal:  J Clin Endocrinol Metab       Date:  2013-12-20       Impact factor: 5.958

2.  Uterine perfusion and hormonal pattern in patients with polycystic ovary syndrome.

Authors:  S Ajossa; S Guerriero; A M Paoletti; M Orrù; S Floris; M Mannias; G B Melis
Journal:  J Assist Reprod Genet       Date:  2001-08       Impact factor: 3.412

Review 3.  Understanding polycystic ovarian syndrome pathogenesis: an updated of its genetic aspects.

Authors:  A E Calogero; V Calabrò; M Catanuso; R A Condorelli; S La Vignera
Journal:  J Endocrinol Invest       Date:  2011-05-23       Impact factor: 4.256

4.  The impact of polycystic ovary syndrome and body mass index on the absorption of recombinant human follicle stimulating hormone.

Authors:  Malinda S Lee; Andrea Lanes; Andrey V Dolinko; Alexandra Bailin; Elizabeth Ginsburg
Journal:  J Assist Reprod Genet       Date:  2020-07-04       Impact factor: 3.412

Review 5.  Polycystic ovarian syndrome: diagnosis and management.

Authors:  Michael T Sheehan
Journal:  Clin Med Res       Date:  2004-02

6.  Naltrexone effect on pulsatile GnRH therapy for ovulation induction in polycystic ovary syndrome: a pilot prospective study.

Authors:  A M Fulghesu; M Ciampelli; C Belosi; R Apa; M Guido; A Caruso; S Mancuso; A Lanzone
Journal:  J Endocrinol Invest       Date:  2001 Jul-Aug       Impact factor: 4.256

Review 7.  Polycystic ovary syndrome in the pediatric population.

Authors:  Andrew A Bremer
Journal:  Metab Syndr Relat Disord       Date:  2010-10       Impact factor: 1.894

8.  Increased androgen response to follicle-stimulating hormone administration in women with polycystic ovary syndrome.

Authors:  Deborah S Wachs; Mickey S Coffler; Pamela J Malcom; Shunichi Shimasaki; R Jeffrey Chang
Journal:  J Clin Endocrinol Metab       Date:  2008-02-19       Impact factor: 5.958

9.  Comparison of clinical features and health manifestations in lean vs. obese Indian women with polycystic ovarian syndrome.

Authors:  Abha Majumdar; Tejshree A Singh
Journal:  J Hum Reprod Sci       Date:  2009-01

10.  Serum C-reactive protein levels in normal-weight polycystic ovary syndrome.

Authors:  Ji Young Oh; Ji-Ah Lee; Hyejin Lee; Jee-Young Oh; Yeon-Ah Sung; Hyewon Chung
Journal:  Korean J Intern Med       Date:  2009-11-27       Impact factor: 2.884

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.